368 active
/
715 total (since 2015)
188
Phase 1 Active
381 total
220
Phase 2 Active
417 total
32
Phase 3 Active
58 total
0
Phase 4 Active
2 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Bristol-Myers Squibb 6 5 4
Takeda 4 2 1
Taiho Oncology, Inc. 4 1 0
Orca Biosystems, Inc. 4 0 0
Novartis 2 1 8
AbbVie 2 1 1
Ascentage Pharma Group Inc. 2 0 0
Ryvu Therapeutics SA 2 0 0
GCP-Service International West GmbH 2 0 0
Akeso 2 0 0
Johnson & Johnson 1 4 1
Bellicum Pharmaceuticals 1 0 4
Celyad Oncology SA 1 2 1
Agios Pharmaceuticals, Inc. 1 1 0
Incyte Corporation 1 0 1
NCT05316701 ACTIVE NOT RECRUITING
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc. n=187
NCT05949684 RECRUITING
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Bristol-Myers Squibb n=360
NCT07396480 RECRUITING
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
First Affiliated Hospital of Zhejiang University n=186
NCT05469737 ACTIVE NOT RECRUITING
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
Bristol-Myers Squibb n=230
NCT07422480 NOT YET RECRUITING
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda n=300
NCT04708054 RECRUITING
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center n=324
NCT06465953 RECRUITING
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Institut de Recherches Internationales Servier n=48
NCT04256317 RECRUITING
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc. n=236
NCT06499285 RECRUITING
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda n=225
NCT02598661 ACTIVE NOT RECRUITING
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Geron Corporation n=289
NCT05457556 ACTIVE NOT RECRUITING
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
Children's Oncology Group n=435
NCT06641414 RECRUITING
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Ascentage Pharma Group Inc. n=490
NCT04064060 RECRUITING
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Celgene n=665
NCT06045689 ACTIVE NOT RECRUITING
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
Bristol-Myers Squibb n=106
NCT03173248 ACTIVE NOT RECRUITING
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Institut de Recherches Internationales Servier n=146
NCT05181592 ACTIVE NOT RECRUITING
Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.
GWT-TUD GmbH n=70
NCT04401748 ACTIVE NOT RECRUITING
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
AbbVie n=531
NCT02521493 ACTIVE NOT RECRUITING
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Children's Oncology Group n=280
NCT06972641 RECRUITING
Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
Ruijin Hospital n=126
NCT04184505 RECRUITING
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
Gruppo Italiano Malattie EMatologiche dell'Adulto n=274
NCT06927232 NOT YET RECRUITING
AZA+Lus VS AZA Monotherapy in HR-MDS
Peking Union Medical College Hospital n=86
NCT05883956 ACTIVE NOT RECRUITING
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Otsuka Australia Pharmaceutical Pty Ltd n=13
NCT03223961 ACTIVE NOT RECRUITING
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
Groupe Francophone des Myelodysplasies n=124
NCT05991908 RECRUITING
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
Shanghai Jiao Tong University School of Medicine n=222
NCT05674539 ENROLLING BY INVITATION
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology n=200
NCT06756152 RECRUITING
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=50
NCT05153226 ACTIVE NOT RECRUITING
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
DKMS gemeinnützige GmbH n=640
NCT04027309 ACTIVE NOT RECRUITING
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
Stichting Hemato-Oncologie voor Volwassenen Nederland n=777
NCT03682536 ACTIVE NOT RECRUITING
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
Celgene n=363
NCT03839771 ACTIVE NOT RECRUITING
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
Stichting Hemato-Oncologie voor Volwassenen Nederland n=968
NCT06475820 ACTIVE NOT RECRUITING
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=150
NCT05515029 ACTIVE NOT RECRUITING
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=56
NCT02730299 COMPLETED
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd n=125
NCT04266301 TERMINATED
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Novartis Pharmaceuticals n=530
NCT03594149 COMPLETED
Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients
Centre Henri Becquerel n=60
NCT03268954 COMPLETED
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
Takeda n=454
NCT05709093 TERMINATED
A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)
TJ Biopharma Co., Ltd. n=10
NCT04797780 TERMINATED
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
Syros Pharmaceuticals n=246
NCT03016130 TERMINATED
Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)
University of Florida n=217
NCT03745716 COMPLETED
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Aprea Therapeutics n=154
NCT03092674 COMPLETED
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI) n=76
NCT02907359 COMPLETED
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Astex Pharmaceuticals, Inc. n=417
NCT03306264 COMPLETED
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
Astex Pharmaceuticals, Inc. n=227
NCT03275636 COMPLETED
Haploidentical Donor vs mMUD in Hematological Malignancies
DKMS gemeinnützige GmbH n=98
NCT03263091 TERMINATED
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
Kyntra Bio n=184
NCT04313881 TERMINATED
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
Gilead Sciences n=539
NCT04842604 COMPLETED
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Pfizer n=14
NCT03699475 TERMINATED
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
Bellicum Pharmaceuticals n=1
NCT03303066 COMPLETED
Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)
Kyntra Bio n=43
NCT02942173 COMPLETED
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=150
NCT04326764 TERMINATED
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Goethe University n=52
NCT04095858 TERMINATED
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=11
NCT02562443 TERMINATED
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Traws Pharma, Inc. n=372
NCT02999854 TERMINATED
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
Kiadis Pharma n=63
NCT02744742 COMPLETED
G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University n=202
NCT02631070 COMPLETED
A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Celgene n=229
NCT03066466 WITHDRAWN
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
Loyola University
NCT04284787 ACTIVE NOT RECRUITING
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT05564390 RECRUITING
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
NCT05554419 NOT YET RECRUITING
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT04214249 ACTIVE NOT RECRUITING
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT05600894 ACTIVE NOT RECRUITING
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
National Cancer Institute (NCI)
NCT06577441 RECRUITING
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT07153497 NOT YET RECRUITING
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
National Cancer Institute (NCI)
NCT06303193 NOT YET RECRUITING
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
National Cancer Institute (NCI)
NCT06566742 RECRUITING
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
M.D. Anderson Cancer Center
NCT03289910 ACTIVE NOT RECRUITING
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
NCT03849651 ACTIVE NOT RECRUITING
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT05998408 RECRUITING
JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
National Heart, Lung, and Blood Institute (NHLBI)
NCT05490446 ACTIVE NOT RECRUITING
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Agios Pharmaceuticals, Inc.
NCT06304103 RECRUITING
A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome
Kind Pharmaceuticals LLC
NCT06904482 RECRUITING
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Case Comprehensive Cancer Center
NCT04195633 RECRUITING
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT04061421 RECRUITING
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
Michael Savona
NCT05589896 RECRUITING
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
NCT07387354 NOT YET RECRUITING
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
Thomas Jefferson University
NCT05969860 RECRUITING
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT07216443 RECRUITING
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
NCT05428969 ACTIVE NOT RECRUITING
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Faron Pharmaceuticals Ltd
NCT03672539 ACTIVE NOT RECRUITING
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04655755 ACTIVE NOT RECRUITING
Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
NCT05010122 RECRUITING
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04761770 ACTIVE NOT RECRUITING
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders
Memorial Sloan Kettering Cancer Center
NCT04726241 RECRUITING
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
PedAL BCU, LLC
NCT02861417 ACTIVE NOT RECRUITING
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT03383575 RECRUITING
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT07400341 NOT YET RECRUITING
Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
The First Affiliated Hospital of Soochow University
NCT04419649 RECRUITING
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Takeda
NCT06001385 ACTIVE NOT RECRUITING
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Center for International Blood and Marrow Transplant Research
NCT03173937 RECRUITING
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
National Heart, Lung, and Blood Institute (NHLBI)
NCT03520647 RECRUITING
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
National Heart, Lung, and Blood Institute (NHLBI)
NCT05092451 ACTIVE NOT RECRUITING
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
NCT05732103 RECRUITING
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Chordia Therapeutics, Inc.
NCT04742634 RECRUITING
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
Washington University School of Medicine
NCT06063486 RECRUITING
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
University of Southern California
NCT06091267 ACTIVE NOT RECRUITING
PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes
Otsuka Beijing Research Institute
NCT03579875 RECRUITING
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
Masonic Cancer Center, University of Minnesota
NCT07046078 RECRUITING
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Fred Hutchinson Cancer Center
NCT07155226 RECRUITING
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
AstraZeneca
NCT02935361 ACTIVE NOT RECRUITING
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
University of Southern California
NCT03164057 ACTIVE NOT RECRUITING
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
NCT04262843 ACTIVE NOT RECRUITING
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia
City of Hope Medical Center
NCT03842696 ACTIVE NOT RECRUITING
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
NCT04994808 ACTIVE NOT RECRUITING
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
NCT05320198 RECRUITING
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Disc Medicine, Inc
NCT06013423 RECRUITING
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
NCT07228273 RECRUITING
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
OHSU Knight Cancer Institute
NCT04187105 RECRUITING
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
University of Illinois at Chicago
NCT03121014 ACTIVE NOT RECRUITING
Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
University of Illinois at Chicago
NCT03862157 ACTIVE NOT RECRUITING
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT04550442 ACTIVE NOT RECRUITING
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
NCT03661307 RECRUITING
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04644016 RECRUITING
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
NCT05201066 ACTIVE NOT RECRUITING
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Novartis Pharmaceuticals
NCT07319845 NOT YET RECRUITING
A Study of TAK-226 for Transfusion-Dependent Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes
Takeda
NCT05184842 RECRUITING
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Montefiore Medical Center
NCT03404193 ACTIVE NOT RECRUITING
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT05365035 RECRUITING
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
M.D. Anderson Cancer Center
NCT07301866 RECRUITING
A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.
Ciusss de L'Est de l'Île de Montréal
NCT04269213 ACTIVE NOT RECRUITING
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
Roswell Park Cancer Institute
NCT07285044 RECRUITING
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT05379166 ACTIVE NOT RECRUITING
Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome
Uma Borate
NCT07052006 ACTIVE NOT RECRUITING
A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia
Halia Therapeutics, Inc.
NCT04802161 ACTIVE NOT RECRUITING
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
National Cancer Institute (NCI)
NCT03128034 RECRUITING
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Fred Hutchinson Cancer Center
NCT04068597 RECRUITING
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
NCT03622788 ACTIVE NOT RECRUITING
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
NCT04128748 RECRUITING
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04047641 RECRUITING
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT05177211 ACTIVE NOT RECRUITING
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
H. Lee Moffitt Cancer Center and Research Institute
NCT03564873 ACTIVE NOT RECRUITING
Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
University of Colorado, Denver
NCT05782127 ACTIVE NOT RECRUITING
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies
NCT06680752 RECRUITING
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
ARCE Therapeutics, Inc.
NCT05732961 RECRUITING
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
NCT05181735 RECRUITING
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Groupe Francophone des Myelodysplasies
NCT03330821 ACTIVE NOT RECRUITING
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
University of Southern California
NCT03300492 RECRUITING
Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS
University Hospital, Basel, Switzerland
NCT05194397 RECRUITING
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Children's Hospital of Philadelphia
NCT07238686 RECRUITING
Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
Beijing 302 Hospital
NCT04493164 RECRUITING
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03589729 RECRUITING
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
M.D. Anderson Cancer Center
NCT07238712 RECRUITING
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
St. Petersburg State Pavlov Medical University
NCT04239157 RECRUITING
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
NCT04060277 ACTIVE NOT RECRUITING
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT03747757 ACTIVE NOT RECRUITING
Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue
M.D. Anderson Cancer Center
NCT06928662 RECRUITING
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Fred Hutchinson Cancer Center
NCT04093570 ENROLLING BY INVITATION
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Taiho Oncology, Inc.
NCT06128070 RECRUITING
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
City of Hope Medical Center
NCT04798339 ACTIVE NOT RECRUITING
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
H. Lee Moffitt Cancer Center and Research Institute
NCT05285813 ACTIVE NOT RECRUITING
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
M.D. Anderson Cancer Center
NCT06113302 RECRUITING
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
NCT04797000 ACTIVE NOT RECRUITING
Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence
Novartis Pharmaceuticals
NCT05308264 RECRUITING
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Rigel Pharmaceuticals
NCT03670966 RECRUITING
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT03779854 RECRUITING
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT06529731 RECRUITING
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Sawa Ito, MD
NCT06597734 RECRUITING
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
NCT02392572 RECRUITING
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04493138 RECRUITING
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
M.D. Anderson Cancer Center
NCT07214064 NOT YET RECRUITING
Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation
University Hospital Tuebingen
NCT06315309 RECRUITING
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
NCT05796570 RECRUITING
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Franziska Wachter
NCT06265584 RECRUITING
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
NCT05226455 RECRUITING
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
Groupe Francophone des Myelodysplasies
NCT06548230 RECRUITING
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
NCT03471260 RECRUITING
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
M.D. Anderson Cancer Center
NCT05211570 RECRUITING
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
AB Science
NCT05693909 RECRUITING
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
Pharmacosmos A/S
NCT02530463 ACTIVE NOT RECRUITING
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04282187 RECRUITING
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
NCT06704152 RECRUITING
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
BlueSphere Bio, Inc
NCT06599762 RECRUITING
Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
University of Manitoba
NCT03970096 RECRUITING
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
NCT06918834 RECRUITING
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
Institute of Hematology & Blood Diseases Hospital, China
NCT03953898 ACTIVE NOT RECRUITING
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
National Cancer Institute (NCI)
NCT06859424 RECRUITING
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research
NCT03214562 RECRUITING
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03683433 RECRUITING
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
M.D. Anderson Cancer Center
NCT04734990 RECRUITING
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
NCT05884333 RECRUITING
Cord Blood Transplant in Adults With Blood Cancers
Memorial Sloan Kettering Cancer Center
NCT04872595 ACTIVE NOT RECRUITING
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
Memorial Sloan Kettering Cancer Center
NCT07025824 NOT YET RECRUITING
Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
Technische Universität Dresden
NCT03850574 RECRUITING
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Aptose Biosciences Inc.
NCT03399773 ACTIVE NOT RECRUITING
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
NCT02506933 ACTIVE NOT RECRUITING
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT04278768 RECRUITING
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Curis, Inc.
NCT02790515 ACTIVE NOT RECRUITING
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
NCT04904588 ACTIVE NOT RECRUITING
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT06984536 RECRUITING
Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT
Peking University People's Hospital
NCT06923488 RECRUITING
Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes
West Virginia University
NCT04668885 ACTIVE NOT RECRUITING
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
Case Comprehensive Cancer Center
NCT03739502 RECRUITING
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
University of Rochester
NCT06630221 RECRUITING
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Abhay Singh, MD MPH
NCT06717958 RECRUITING
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
Technische Universität Dresden
NCT05805605 RECRUITING
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT06199557 RECRUITING
A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients
Haukeland University Hospital
NCT06847867 RECRUITING
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
GlaxoSmithKline
NCT06815003 RECRUITING
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
NCT06802315 RECRUITING
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
University of Illinois at Chicago
NCT05800210 RECRUITING
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
University of Florida
NCT06793410 RECRUITING
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Vastra Gotaland Region
NCT06130579 RECRUITING
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
Peking University People's Hospital
NCT05364762 ACTIVE NOT RECRUITING
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
City of Hope Medical Center
NCT06243458 ACTIVE NOT RECRUITING
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
GCP-Service International West GmbH
NCT04730258 ACTIVE NOT RECRUITING
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
Treadwell Therapeutics, Inc
NCT03503409 ACTIVE NOT RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Groupe Francophone des Myelodysplasies
NCT03744390 ACTIVE NOT RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
Groupe Francophone des Myelodysplasies
NCT04482894 ACTIVE NOT RECRUITING
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
University of Virginia
NCT06268574 ACTIVE NOT RECRUITING
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
Ryvu Therapeutics SA
NCT02646839 ENROLLING BY INVITATION
KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
Michael Pulsipher
NCT04861207 ACTIVE NOT RECRUITING
Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes
Maria Sklodowska-Curie National Research Institute of Oncology
NCT04232241 ACTIVE NOT RECRUITING
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
Universitätsklinikum Hamburg-Eppendorf
NCT06355583 RECRUITING
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
Imperial College London
NCT06156579 RECRUITING
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML
University Hospital Tuebingen
NCT05483010 RECRUITING
Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)
Washington University School of Medicine
NCT06900088 NOT YET RECRUITING
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Institute of Hematology & Blood Diseases Hospital, China
NCT06839456 RECRUITING
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT06892223 RECRUITING
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Istituto Clinico Humanitas
NCT04339101 ACTIVE NOT RECRUITING
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
City of Hope Medical Center
NCT05583552 ACTIVE NOT RECRUITING
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
GCP-Service International West GmbH
NCT06059391 RECRUITING
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT04900350 ACTIVE NOT RECRUITING
A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome
Akeso
NCT06299462 RECRUITING
PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
NCT06196203 RECRUITING
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Akeso
NCT02944955 NOT YET RECRUITING
A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
BioLite, Inc.
NCT05601726 RECRUITING
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Advanced BioDesign
NCT06765928 NOT YET RECRUITING
Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT
Ruijin Hospital
NCT06612944 RECRUITING
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT05924100 RECRUITING
Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD
Associazione Qol-one
NCT06664970 ENROLLING BY INVITATION
A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor
Peking Union Medical College Hospital
NCT06471946 RECRUITING
VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
Navy General Hospital, Beijing
NCT06602323 NOT YET RECRUITING
TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
NCT06594965 NOT YET RECRUITING
A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Hansoh BioMedical R&D Company
NCT06598969 NOT YET RECRUITING
TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
NCT06536959 RECRUITING
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Beijing 302 Hospital
NCT06532084 RECRUITING
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
St. Petersburg State Pavlov Medical University
NCT06508099 RECRUITING
Vitamin A and D Supplementation in Allogeneic HCT
St. Petersburg State Pavlov Medical University
NCT06477549 RECRUITING
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
St. Petersburg State Pavlov Medical University
NCT03192397 ACTIVE NOT RECRUITING
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT04806906 ACTIVE NOT RECRUITING
Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients
University of Florence
NCT05807932 RECRUITING
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Heinrich-Heine University, Duesseldorf
NCT06206174 RECRUITING
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Shenzhen TargetRx, Inc.
NCT03412409 RECRUITING
RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT
Peking University People's Hospital
NCT06279494 NOT YET RECRUITING
Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors
Peking University People's Hospital
NCT05925504 RECRUITING
The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes
Institute of Hematology & Blood Diseases Hospital, China
NCT06050941 NOT YET RECRUITING
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS
First Affiliated Hospital of Zhejiang University
NCT06046313 RECRUITING
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
First Affiliated Hospital of Zhejiang University
NCT06235398 NOT YET RECRUITING
Upfront Related Donor Transplantation in Patients With Myelodisplatic Syndrome : a Phase 2 Trial
Assistance Publique - Hôpitaux de Paris
NCT05384691 RECRUITING
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
University of Leipzig
NCT05788679 RECRUITING
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
Karolinska University Hospital
NCT04061239 RECRUITING
Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML
GWT-TUD GmbH
NCT06020833 NOT YET RECRUITING
A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS
Peking Union Medical College Hospital
NCT05817955 RECRUITING
Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN
The First Affiliated Hospital with Nanjing Medical University
NCT04935684 RECRUITING
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
University Hospital, Clermont-Ferrand
NCT05584761 RECRUITING
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
The First Affiliated Hospital with Nanjing Medical University
NCT03852407 RECRUITING
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
University of Liege
NCT05025098 RECRUITING
Precision Therapy Versus Standard Therapy in AML and MDS in Elderly
University Hospital, Akershus
NCT03886662 RECRUITING
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Lixte Biotechnology Holdings, Inc.
NCT02286726 COMPLETED
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT04620681 COMPLETED
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
H. Lee Moffitt Cancer Center and Research Institute
NCT06284460 WITHDRAWN
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
M.D. Anderson Cancer Center
NCT04160052 TERMINATED
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03502668 COMPLETED
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Taiho Oncology, Inc.
NCT03946670 TERMINATED
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
Novartis Pharmaceuticals
NCT05120570 COMPLETED
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Masonic Cancer Center, University of Minnesota
NCT05115630 COMPLETED
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
M.D. Anderson Cancer Center
NCT05086315 TERMINATED
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sanofi
NCT04191187 COMPLETED
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
NCT05918055 TERMINATED
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
NCT02684162 COMPLETED
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant
M.D. Anderson Cancer Center
NCT04874194 TERMINATED
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
M.D. Anderson Cancer Center
NCT05568225 TERMINATED
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
Forma Therapeutics, Inc.
NCT04582539 TERMINATED
To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma
Incyte Corporation
NCT04878432 TERMINATED
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
Novartis Pharmaceuticals
NCT06563804 TERMINATED
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Servier Bio-Innovation LLC
NCT04812548 TERMINATED
A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants
Novartis Pharmaceuticals
NCT05358808 TERMINATED
ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
TC Biopharm
NCT02356159 COMPLETED
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Cancer Institute (NCI)
NCT02438761 TERMINATED
PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)
Institut Curie
NCT02793544 COMPLETED
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT04539236 SUSPENDED
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Mikkael Sekeres, MD
NCT04849910 TERMINATED
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Vor Biopharma
NCT02722668 COMPLETED
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
NCT03333486 TERMINATED
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
NCT02719574 COMPLETED
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
Forma Therapeutics, Inc.
NCT05024994 COMPLETED
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Memorial Sloan Kettering Cancer Center
NCT02397720 COMPLETED
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02220985 COMPLETED
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
NCT03246906 TERMINATED
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
NCT04752163 TERMINATED
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT04827719 COMPLETED
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
Groupe Francophone des Myelodysplasies
NCT04857645 COMPLETED
ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
Groupe Francophone des Myelodysplasies
NCT03184935 SUSPENDED
Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)
Sclnow Biotechnology Co., Ltd.
NCT02566304 COMPLETED
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT03434730 COMPLETED
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
NCT04487106 COMPLETED
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT05766514 WITHDRAWN
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
University of Florida
NCT02658487 COMPLETED
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
NCT03150004 TERMINATED
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Medical College of Wisconsin
NCT02649790 COMPLETED
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Karyopharm Therapeutics Inc
NCT03931291 COMPLETED
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Aprea Therapeutics
NCT03011034 COMPLETED
Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Janssen Research & Development, LLC
NCT02396134 COMPLETED
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT04083170 TERMINATED
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
NCT03318159 COMPLETED
Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients
Seoul National University Hospital
NCT02807558 COMPLETED
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Syros Pharmaceuticals
NCT03486353 WITHDRAWN
A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
Fujifilm Pharmaceuticals U.S.A., Inc.
NCT04079296 COMPLETED
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
Astellas Pharma Global Development, Inc.
NCT04762875 TERMINATED
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Ensoma
NCT03238248 COMPLETED
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
Vanderbilt-Ingram Cancer Center
NCT02532231 COMPLETED
Nivolumab in AML in Remission at High Risk for Relapse
M.D. Anderson Cancer Center
NCT03900715 COMPLETED
An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion
Celgene
NCT04151706 COMPLETED
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Robert Lowsky
NCT03941769 COMPLETED
2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
M.D. Anderson Cancer Center
NCT04943757 COMPLETED
Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies
St. Petersburg State Pavlov Medical University
NCT02281084 COMPLETED
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
Celgene
NCT05835011 TERMINATED
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
Astex Pharmaceuticals, Inc.
NCT04522895 COMPLETED
IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT
Heinrich-Heine University, Duesseldorf
NCT03957876 TERMINATED
CPX-351 Therapy for MDS After Hypomethylating Agent Failure
Case Comprehensive Cancer Center
NCT05178342 TERMINATED
Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948
University of Leipzig
NCT02626715 COMPLETED
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
Randy Windreich
NCT03176277 TERMINATED
A Study of ONO-7475 in Patients With Acute Leukemias
Ono Pharmaceutical Co. Ltd
NCT03088709 TERMINATED
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Loyola University
NCT06337331 WITHDRAWN
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
Northside Hospital, Inc.
NCT03493646 COMPLETED
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
Kirby Institute
NCT04526288 TERMINATED
CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease
Fred Hutchinson Cancer Center
NCT03175978 TERMINATED
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
IGF Oncology, LLC
NCT03047993 COMPLETED
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04942730 COMPLETED
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
St. Petersburg State Pavlov Medical University
NCT05237713 TERMINATED
Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
University of Leipzig
NCT05895201 WITHDRAWN
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
NCT04691141 TERMINATED
A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)
Shanghai Antengene Corporation Limited
NCT04202003 COMPLETED
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
TJ Biopharma Co., Ltd.
NCT05367401 WITHDRAWN
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Novartis Pharmaceuticals
NCT03433781 COMPLETED
A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations
NYU Langone Health
NCT02508324 TERMINATED
IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Weill Medical College of Cornell University
NCT05168904 SUSPENDED
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
Cyclacel Pharmaceuticals, Inc.
NCT03128359 COMPLETED
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
NCT03734601 COMPLETED
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
NCT05201183 WITHDRAWN
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Naoyuki G. Saito, M.D., Ph.D.
NCT02509546 COMPLETED
8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT03593915 TERMINATED
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Sumitomo Pharma America, Inc.
NCT04623996 TERMINATED
A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS
Sumitomo Pharma America, Inc.
NCT04055844 COMPLETED
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Masonic Cancer Center, University of Minnesota
NCT02639559 COMPLETED
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
NCT02989844 COMPLETED
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
Masonic Cancer Center, University of Minnesota
NCT02969980 COMPLETED
Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS
Asan Medical Center
NCT03096782 COMPLETED
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
NCT02743611 TERMINATED
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Bellicum Pharmaceuticals
NCT03733249 TERMINATED
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
NCT02661035 COMPLETED
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT03067571 TERMINATED
Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04712942 COMPLETED
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
University of Leipzig
NCT02335268 COMPLETED
Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
NCT03030612 COMPLETED
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
OncoVerity, Inc.
NCT02842827 COMPLETED
A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
NCT02728050 COMPLETED
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
University of Washington
NCT03417154 COMPLETED
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
Masonic Cancer Center, University of Minnesota
NCT04631211 TERMINATED
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Cellphire Therapeutics, Inc.
NCT04146038 COMPLETED
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Rutgers, The State University of New Jersey
NCT02581007 COMPLETED
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital, Inc.
NCT02775903 COMPLETED
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
Celgene
NCT02743351 COMPLETED
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
NCT02431351 WITHDRAWN
Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients
Karyopharm Therapeutics Inc
NCT02593123 COMPLETED
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
NCT04866056 TERMINATED
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT03920657 TERMINATED
Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
Fondazione Italiana Sindromi Mielodisplastiche-ETS
NCT03214666 TERMINATED
GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
GT Biopharma, Inc.
NCT03140280 COMPLETED
Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)
Ehab L Atallah
NCT02556931 COMPLETED
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05246384 WITHDRAWN
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
Rhizen Pharmaceuticals SA
NCT02985190 COMPLETED
A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders
Groupe Francophone des Myelodysplasies
NCT02610777 COMPLETED
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Millennium Pharmaceuticals, Inc.
NCT03434704 COMPLETED
Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole
Ciceri Fabio
NCT02758223 COMPLETED
Prophylactic Application of Donor-derived TCM After Allogeneic HSCT
Wuerzburg University Hospital
NCT04273802 COMPLETED
CPX-351 in Higher Risk Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies
NCT04264806 WITHDRAWN
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
Janssen Research & Development, LLC
NCT02436252 COMPLETED
Study of DSP-7888 in Patients With Myelodysplastic Syndrome
Sumitomo Pharma Co., Ltd.
NCT03600909 TERMINATED
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
Memorial Sloan Kettering Cancer Center
NCT04893915 WITHDRAWN
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Washington University School of Medicine
NCT03151304 TERMINATED
A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes
Helsinn Healthcare SA
NCT03072043 COMPLETED
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
NCT04109690 WITHDRAWN
CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.
Yale University
NCT04044209 WITHDRAWN
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Yale University
NCT03824080 COMPLETED
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes
GWT-TUD GmbH
NCT02795520 TERMINATED
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
OncoTherapy Science, Inc.
NCT02756572 COMPLETED
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
University of Washington
NCT03019939 COMPLETED
Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
M.D. Anderson Cancer Center
NCT02464657 COMPLETED
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
NCT04985656 WITHDRAWN
A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
Takeda
NCT02497404 COMPLETED
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
Weill Medical College of Cornell University
NCT03397173 COMPLETED
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
Case Comprehensive Cancer Center
NCT03602898 WITHDRAWN
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Center
NCT02424968 COMPLETED
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Robert Lowsky
NCT04395092 WITHDRAWN
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
Kiadis Pharma
NCT02500550 COMPLETED
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Kiadis Pharma
NCT03466320 COMPLETED
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
Celyad Oncology SA
NCT03929211 WITHDRAWN
CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome
Wake Forest University Health Sciences
NCT02648932 TERMINATED
The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients
University of Chicago
NCT03113071 TERMINATED
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
Fox Chase Cancer Center
NCT02462252 COMPLETED
Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome
BioLineRx, Ltd.
NCT02240706 TERMINATED
Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes
Boehringer Ingelheim
NCT03338348 COMPLETED
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
University of Ulm
NCT02953561 TERMINATED
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02458235 COMPLETED
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
University of California, San Francisco
NCT02991898 TERMINATED
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT03059615 WITHDRAWN
A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS
Immune System Key Ltd
NCT04013880 WITHDRAWN
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
NCT02943668 TERMINATED
Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT03718143 TERMINATED
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
NYU Langone Health
NCT02923986 WITHDRAWN
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Bio-Path Holdings, Inc.
NCT02472691 COMPLETED
Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT
Heinrich-Heine University, Duesseldorf
NCT02921061 COMPLETED
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
Fred Hutchinson Cancer Center
NCT03195010 TERMINATED
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
NCT02399917 TERMINATED
Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02666950 COMPLETED
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Mayo Clinic
NCT02447666 COMPLETED
Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
Celgene
NCT02929498 TERMINATED
Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)
GlaxoSmithKline
NCT03146871 TERMINATED
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent
University of Southern California
NCT03259516 TERMINATED
Nivolumab With Chemotherapy in Refractory MDS
St. Petersburg State Pavlov Medical University
NCT02627573 TERMINATED
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
St. Petersburg State Pavlov Medical University
NCT02418000 TERMINATED
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations
Spirita Oncology, LLC
NCT02706899 TERMINATED
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
Seagen Inc.
NCT02363491 COMPLETED
A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome
Opsona Therapeutics Ltd.
NCT03337451 COMPLETED
Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome
Opsona Therapeutics Ltd.
NCT03438344 WITHDRAWN
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT03365661 WITHDRAWN
QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML
Masonic Cancer Center, University of Minnesota
NCT02477631 COMPLETED
Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients
Sheba Medical Center
NCT02992860 TERMINATED
Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY
GWT-TUD GmbH
NCT02732184 COMPLETED
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
Aeglea Biotherapeutics
NCT02550535 COMPLETED
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients
Cell Medica Ltd
NCT02928419 TERMINATED
Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q
Associazione Qol-one
NCT02663752 TERMINATED
A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.
Novartis Pharmaceuticals
NCT02452346 COMPLETED
Study of Clinical Efficacy and Safety of Tosedostat in MDS
Weill Medical College of Cornell University
NCT02877082 TERMINATED
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Emory University
NCT02204020 WITHDRAWN
Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS
University of Pittsburgh
NCT02269579 WITHDRAWN
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
Jazz Pharmaceuticals
NCT02198482 TERMINATED
Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
University of Ulm
NCT02433483 TERMINATED
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
St. Jude Children's Research Hospital
NCT02829840 WITHDRAWN
Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
NCT02835794 WITHDRAWN
A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)
University of Florida
NCT01520805 WITHDRAWN
Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
Cornerstone Pharmaceuticals
NCT01010373 SUSPENDED
Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients
BioMAS Ltd
NCT07384715 RECRUITING
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Genmab
NCT04190550 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT06484062 RECRUITING
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
National Cancer Institute (NCI)
NCT03816319 RECRUITING
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
NCT07044544 RECRUITING
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
University of Alabama at Birmingham
NCT07283094 RECRUITING
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
Montefiore Medical Center
NCT06846606 ACTIVE NOT RECRUITING
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Auron Therapeutics, Inc.
NCT03630991 RECRUITING
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
M.D. Anderson Cancer Center
NCT04279847 ACTIVE NOT RECRUITING
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Incyte Corporation
NCT06247787 RECRUITING
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Children's Oncology Group
NCT03802695 RECRUITING
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
NCT06034470 RECRUITING
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Fred Hutchinson Cancer Center
NCT03896269 RECRUITING
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
NCT06616636 RECRUITING
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
M.D. Anderson Cancer Center
NCT06656494 RECRUITING
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
NCT06372717 RECRUITING
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Apollo Therapeutics Ltd
NCT06551584 RECRUITING
Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Stanford University
NCT07270978 RECRUITING
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
University of Virginia
NCT07321626 RECRUITING
Romiplostim N01 for Platelet Recovery After Haploidentical HSCT
First Affiliated Hospital of Zhejiang University
NCT05455294 ACTIVE NOT RECRUITING
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
Jacqueline Garcia, MD
NCT06326463 RECRUITING
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
St. Jude Children's Research Hospital
NCT06359002 ACTIVE NOT RECRUITING
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
Byondis B.V.
NCT04953897 RECRUITING
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Taiho Oncology, Inc.
NCT04953910 RECRUITING
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Taiho Oncology, Inc.
NCT06146257 RECRUITING
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
GluBio Therapeutics Inc.
NCT07347171 RECRUITING
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Cullgen (Shanghai),Inc
NCT07347418 NOT YET RECRUITING
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS
University of Colorado, Denver
NCT05143996 RECRUITING
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cullinan Therapeutics Inc.
NCT07006025 RECRUITING
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
Treebough Therapies
NCT05362773 RECRUITING
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
NCT05342584 RECRUITING
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
Montefiore Medical Center
NCT02530034 ACTIVE NOT RECRUITING
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
NCT03912064 ACTIVE NOT RECRUITING
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Dana-Farber Cancer Institute
NCT06138587 RECRUITING
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute
NCT04024761 RECRUITING
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Dana-Farber Cancer Institute
NCT03613532 ACTIVE NOT RECRUITING
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Jacqueline Garcia, MD
NCT07302776 NOT YET RECRUITING
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
NCT04245397 RECRUITING
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Syntrix Biosystems, Inc.
NCT05088356 RECRUITING
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford University
NCT06552416 RECRUITING
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
Marker Therapeutics, Inc.
NCT03560752 ACTIVE NOT RECRUITING
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
City of Hope Medical Center
NCT05564650 ACTIVE NOT RECRUITING
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
NCT04227847 RECRUITING
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Seagen, a wholly owned subsidiary of Pfizer
NCT03969446 RECRUITING
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
City of Hope Medical Center
NCT04608110 RECRUITING
A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
Taiho Pharmaceutical Co., Ltd.
NCT05534620 RECRUITING
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
medac GmbH
NCT05636514 RECRUITING
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
Clinical Hub for Interventional Research (CHOIR)
NCT07254793 NOT YET RECRUITING
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
University of Arizona
NCT03326921 RECRUITING
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT05146739 ACTIVE NOT RECRUITING
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane
National Cancer Institute (NCI)
NCT03494569 RECRUITING
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT06195891 RECRUITING
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT05986240 RECRUITING
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Montefiore Medical Center
NCT03113643 RECRUITING
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Dana-Farber Cancer Institute
NCT06419634 RECRUITING
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Bristol-Myers Squibb
NCT06533761 RECRUITING
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Stelexis BioSciences
NCT02494167 ACTIVE NOT RECRUITING
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)
Baylor College of Medicine
NCT02508038 RECRUITING
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
NCT06788509 ENROLLING BY INVITATION
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
NCT03017820 RECRUITING
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
NCT06465160 RECRUITING
A Study to Evaluate the MNV-201 in Patients With Low Risk MDS
Minovia Therapeutics Ltd.
NCT03770429 ACTIVE NOT RECRUITING
AZD6738 for Patients With Progressive MDS or CMML
Massachusetts General Hospital
NCT05292664 ACTIVE NOT RECRUITING
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Andrew E. Place, MD
NCT06501196 RECRUITING
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
NCT06994676 RECRUITING
A Study of CBX-250 in Participants With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Crossbow Therapeutics, Inc.
NCT05823571 ACTIVE NOT RECRUITING
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04281199 ACTIVE NOT RECRUITING
TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT
City of Hope Medical Center
NCT06280482 RECRUITING
Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)
The University of Texas Health Science Center, Houston
NCT02890329 ACTIVE NOT RECRUITING
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT06021600 ACTIVE NOT RECRUITING
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
M.D. Anderson Cancer Center
NCT03874052 RECRUITING
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Jennifer Saultz
NCT07131085 NOT YET RECRUITING
QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)
Anhui Provincial Hospital
NCT06378437 RECRUITING
A Study of GLB-001 in Patients With Myeloid Malignancies
Hangzhou GluBio Pharmaceutical Co., Ltd.
NCT04375631 RECRUITING
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Fred Hutchinson Cancer Center
NCT06357182 RECRUITING
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
OHSU Knight Cancer Institute
NCT03843528 ACTIVE NOT RECRUITING
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
Johns Hopkins All Children's Hospital
NCT07107126 NOT YET RECRUITING
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Remedy Plan, Inc.
NCT02942290 ACTIVE NOT RECRUITING
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
AbbVie
NCT06670222 RECRUITING
Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
Groupe Francophone des Myelodysplasies
NCT06287944 RECRUITING
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
City of Hope Medical Center
NCT04980404 ACTIVE NOT RECRUITING
Inqovi Maintenance Therapy in Myeloid Neoplasms
Massachusetts General Hospital
NCT05703542 RECRUITING
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Eric Stephen Winer, MD
NCT04891757 ACTIVE NOT RECRUITING
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Foghorn Therapeutics Inc.
NCT05139004 ACTIVE NOT RECRUITING
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT06594445 RECRUITING
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Masonic Cancer Center, University of Minnesota
NCT04603001 ACTIVE NOT RECRUITING
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Eli Lilly and Company
NCT03232268 ACTIVE NOT RECRUITING
HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies
Institut Paoli-Calmettes
NCT07020533 NOT YET RECRUITING
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT06996119 NOT YET RECRUITING
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
City of Hope Medical Center
NCT05320809 ACTIVE NOT RECRUITING
Study of 3D189 in Patients With Hematologic Malignancies
3D Medicines
NCT05829226 RECRUITING
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
PureTech
NCT05473910 RECRUITING
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
TScan Therapeutics, Inc.
NCT04013685 ACTIVE NOT RECRUITING
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
NCT06047886 RECRUITING
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
NCT06462365 RECRUITING
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
NCT02632708 ACTIVE NOT RECRUITING
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Institut de Recherches Internationales Servier
NCT03572764 ACTIVE NOT RECRUITING
CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
Washington University School of Medicine
NCT06399640 RECRUITING
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
NCT06820268 RECRUITING
A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
NovaOnco Therapeutics Co., Ltd.
NCT06498973 RECRUITING
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT06502145 RECRUITING
Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome
Medical College of Wisconsin
NCT06543381 RECRUITING
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT04250051 ACTIVE NOT RECRUITING
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
Northwestern University
NCT04623944 ACTIVE NOT RECRUITING
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
Nkarta, Inc.
NCT05476770 RECRUITING
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT06034275 RECRUITING
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Vincerx Pharma, Inc.
NCT03927261 ACTIVE NOT RECRUITING
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
Precigen, Inc
NCT04275518 RECRUITING
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Ascentage Pharma Group Inc.
NCT06550713 RECRUITING
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT04365179 RECRUITING
Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
Immune System Key Ltd
NCT06463327 NOT YET RECRUITING
ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML
TC Biopharm
NCT03560882 ACTIVE NOT RECRUITING
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
Joaquina Baranda
NCT04243785 RECRUITING
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Edgewood Oncology Inc.
NCT03291444 RECRUITING
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Zhujiang Hospital
NCT05607199 RECRUITING
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Aurigene Discovery Technologies Limited
NCT05005299 RECRUITING
Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation
Melbourne Health
NCT02477878 ACTIVE NOT RECRUITING
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
NCT04999943 RECRUITING
Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome
Affiliated Hospital to Academy of Military Medical Sciences
NCT04167696 RECRUITING
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Celyad Oncology SA
NCT06888323 SUSPENDED
Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment
National Cancer Institute (NCI)
NCT03772925 TERMINATED
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
NCT03358719 COMPLETED
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
NCT05170828 WITHDRAWN
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
NCT04915612 COMPLETED
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT03600155 COMPLETED
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04328714 TERMINATED
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease
Edwin Horwitz
NCT06492707 SUSPENDED
DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial
Fred Hutchinson Cancer Center
NCT02381548 TERMINATED
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT05787496 TERMINATED
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
NCT05665530 COMPLETED
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
NCT03932643 COMPLETED
ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant
University of Nebraska
NCT02312102 COMPLETED
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
NCT03573310 COMPLETED
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
Janssen Research & Development, LLC
NCT06294275 COMPLETED
A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects
Longbio Pharma
NCT06454409 SUSPENDED
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
NCT05400122 SUSPENDED
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
David Wald
NCT04937166 TERMINATED
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Kahr Medical
NCT02996773 COMPLETED
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
NCT03940352 TERMINATED
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals
NCT04810611 TERMINATED
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
Novartis Pharmaceuticals
NCT04609826 COMPLETED
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Janssen Research & Development, LLC
NCT05168202 TERMINATED
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bristol-Myers Squibb
NCT05961839 TERMINATED
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Schrödinger, Inc.
NCT04951778 TERMINATED
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Celgene
NCT04417517 TERMINATED
A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)
ALX Oncology Inc.
NCT05209152 TERMINATED
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
Amgen
NCT02446964 COMPLETED
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia
City of Hope Medical Center
NCT02848001 TERMINATED
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Celgene
NCT06572631 WITHDRAWN
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
City of Hope Medical Center
NCT03915379 COMPLETED
A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Janssen Research & Development, LLC
NCT03066648 COMPLETED
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis Pharmaceuticals
NCT03286114 TERMINATED
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
University of Michigan Rogel Cancer Center
NCT03813147 COMPLETED
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
NCT03755414 COMPLETED
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT02936752 COMPLETED
Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents
National Cancer Institute (NCI)
NCT04638309 TERMINATED
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
Aprea Therapeutics
NCT04477291 TERMINATED
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Aptose Biosciences Inc.
NCT05030675 COMPLETED
Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents
M.D. Anderson Cancer Center
NCT05275439 COMPLETED
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
NCT03939585 WITHDRAWN
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Leland Metheny
NCT02846376 TERMINATED
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
Hackensack Meridian Health
NCT05823480 WITHDRAWN
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
City of Hope Medical Center
NCT03884829 TERMINATED
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Cyclacel Pharmaceuticals, Inc.
NCT04017546 COMPLETED
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
Cyclacel Pharmaceuticals, Inc.
NCT03814005 COMPLETED
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
NCT03187288 COMPLETED
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
University Health Network, Toronto
NCT04901416 COMPLETED
Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS
Coeptis Therapeutics
NCT03198234 TERMINATED
Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders
Roncarolo, Maria Grazia, MD
NCT05933070 TERMINATED
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
Inmune Bio, Inc.
NCT03878524 TERMINATED
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
NCT04912063 TERMINATED
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
AbbVie
NCT02841540 TERMINATED
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
Hemavant Sciences GmbH
NCT05107856 TERMINATED
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
NCT02367456 COMPLETED
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
Pfizer
NCT04718844 COMPLETED
A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome
Silence Therapeutics plc
NCT04439006 COMPLETED
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Jennifer Woyach
NCT04361058 WITHDRAWN
Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
SCRI Development Innovations, LLC
NCT02543879 COMPLETED
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
Forma Therapeutics, Inc.
NCT02498665 COMPLETED
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
NCT02782468 COMPLETED
A Study of Pevonedistat in Adult East Asian Participants
Millennium Pharmaceuticals, Inc.
NCT02916979 COMPLETED
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
Dartmouth-Hitchcock Medical Center
NCT02649764 COMPLETED
Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT05456269 WITHDRAWN
A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS
Race Oncology Ltd
NCT02122081 COMPLETED
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Sumithira Vasu
NCT04402541 COMPLETED
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
Cleave Therapeutics, Inc.
NCT04443751 COMPLETED
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Jiangsu HengRui Medicine Co., Ltd.
NCT02966782 COMPLETED
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)
AbbVie
NCT03465540 TERMINATED
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Amgen
NCT02890758 COMPLETED
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Brenda Cooper, MD
NCT02960646 COMPLETED
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
NCT04485065 SUSPENDED
Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS
Innovent Biologics (Suzhou) Co. Ltd.
NCT03746041 COMPLETED
A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
University of Rochester
NCT02783547 WITHDRAWN
Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome
SymBio Pharmaceuticals
NCT03495167 COMPLETED
Study of SyB C-1101 in Patients With Myelodysplastic Syndrome
SymBio Pharmaceuticals
NCT04543305 COMPLETED
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
Prelude Therapeutics
NCT04022785 COMPLETED
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT02553941 COMPLETED
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
Brian Jonas
NCT03483324 COMPLETED
Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation
Angiocrine Bioscience
NCT02979366 COMPLETED
Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
Institut de Recherches Internationales Servier
NCT03787498 COMPLETED
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Opna Bio LLC
NCT03696537 TERMINATED
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
Naoyuki G. Saito, M.D., Ph.D.
NCT03459859 COMPLETED
Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS
Justin Watts, MD
NCT03519984 TERMINATED
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
University of Southern California
NCT03263637 COMPLETED
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
AstraZeneca
NCT03359460 COMPLETED
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome
Brian Jonas
NCT03516591 COMPLETED
A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes
Amphivena Therapeutics, Inc.
NCT03588936 TERMINATED
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Medical College of Wisconsin
NCT04464889 WITHDRAWN
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
NCT03074006 COMPLETED
Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS
MedPacto, Inc.
NCT03057990 WITHDRAWN
Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)
Montefiore Medical Center
NCT03018223 COMPLETED
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
H. Lee Moffitt Cancer Center and Research Institute
NCT03555955 COMPLETED
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
Jazz Pharmaceuticals
NCT03885947 COMPLETED
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Alla Keyzner
NCT02485535 COMPLETED
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
University of Chicago
NCT04511975 SUSPENDED
A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS
Innovent Biologics (Suzhou) Co. Ltd.
NCT02750995 COMPLETED
Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML
Daniel El Fassi
NCT02750254 TERMINATED
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT02786485 WITHDRAWN
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
Bellicum Pharmaceuticals
NCT03807063 WITHDRAWN
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT04176653 WITHDRAWN
Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124
Silence Therapeutics plc
NCT02370888 TERMINATED
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
University of Florida
NCT02995655 COMPLETED
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Washington University School of Medicine
NCT02909972 COMPLETED
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Aileron Therapeutics, Inc.
NCT03612739 WITHDRAWN
EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
Celyad Oncology SA
NCT02167958 COMPLETED
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Rafic Farah, MD
NCT02508870 COMPLETED
A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Hoffmann-La Roche
NCT03735446 TERMINATED
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Dana-Farber Cancer Institute
NCT02920541 COMPLETED
Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
Institut de Recherches Internationales Servier
NCT02749708 TERMINATED
Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02492737 COMPLETED
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
Agios Pharmaceuticals, Inc.
NCT02678338 COMPLETED
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
Gilead Sciences
NCT02323139 COMPLETED
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
Groupe Francophone des Myelodysplasies
NCT02676323 TERMINATED
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
NCT02641002 TERMINATED
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
Celgene
NCT02728700 TERMINATED
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Stanford University
NCT02721875 TERMINATED
Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes
Boehringer Ingelheim
NCT02203825 COMPLETED
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Celyad Oncology SA
NCT02564536 WITHDRAWN
Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
Washington University School of Medicine
NCT03176849 COMPLETED
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT
Phoenix Children's Hospital
Data: ClinicalTrials.gov